Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 103

BIOTECHNOLOGY in the Future: 2050 (Artificial Biology)

Biopunk androids replicants.

What happens when humans begin combining biology with technology, harnessing the power to recode life itself.

What does the future of biotechnology and genetic engineering look like? How will humans program biology to create organ farm technology and bio-robots. And what happens when companies begin investing in advanced bio-printing, artificial wombs, and cybernetic prosthetic limbs.

Other topic include: bioengineered food and farming, bio-printing in space, new age living bioarchitecture (eco concrete inspired by coral reefs), bioengineered bioluminescence, cyberpunks and biopunks who experiment underground — creating new age food and pets, the future of bionics, corporations owning bionic limbs, the multi-trillion dollar industry of bio-robots, and bioengineered humans with super powers (Neo-Humans).

As well as the future of biomedical engineering, biochemistry, and biodiversity.

Continue reading “BIOTECHNOLOGY in the Future: 2050 (Artificial Biology)” | >

Scientists May Have Found Traces of an Extinct Genetic Code That Came Before DNA

“ tabindex=”0” amino acids and incorporated sulfur-based compounds much earlier than previously thought. This challenges long-standing experiments and opens the door to the possibility that extinct genetic codes existed before ours.

Cracking the Code of Life’s Origins

Despite awe-inspiring diversity, nearly all life on Earth — from tiny bacteria to massive blue whales — shares the same genetic code. But exactly how and when this code emerged remains a topic of scientific debate.

Revolutionary Biology Discovery Combines DNA and RNA To Fight Cancer

A study reveals DNA

DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Forget Silicon — DNA Might Be the Future of Quantum Computing

Researchers have uncovered a way to manipulate DNA

DNA, or deoxyribonucleic acid, is a molecule composed of two long strands of nucleotides that coil around each other to form a double helix. It is the hereditary material in humans and almost all other organisms that carries genetic instructions for development, functioning, growth, and reproduction. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Reducing Immunoglobulin G Improves Metabolic Health And Extends Lifespan

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

Continue reading “Reducing Immunoglobulin G Improves Metabolic Health And Extends Lifespan” | >

Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in Cancer

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice. Their work establishes a next-generation gene-editing tool that enhances genetic manipulation for cancer and medical research in a preclinical model.

The study, “Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening,” was published in Nature Communications.

“This is the first time Cas12a has been used in preclinical models, which will greatly advance our genome engineering capabilities,” said co-author Eddie La Marca, PhD, a postdoctoral researcher at the Olivia Newton-John Cancer Research Institute (ONJCRI) in Australia.

Genetics, Not Maternal Sickness, Drives Autism Risk

Health during pregnancy does not cause autism, according to a study of 1.1M pregnancies. Genetics and fetal complications play a much larger role, challenging long-held assumptions about autism risk factors. +.

Summary: A large study analyzing over 1.1 million pregnancies found no strong evidence that maternal health conditions during pregnancy cause autism. Instead, nearly all previously reported associations between maternal diagnoses and autism could be explained by genetic or environmental factors.

Researchers found that only fetal complications remained statistically linked to autism, suggesting these issues might be early signs rather than causes. By analyzing sibling and paternal health records, the study further ruled out many maternal conditions as contributing factors.

The findings emphasize that autism likely begins before birth due to genetic influences rather than maternal health conditions. This research may help alleviate guilt for parents and shift focus toward early diagnosis and support.

Complex engineering of human cell lines reveals genome’s unexpected resilience to structural changes

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

Researchers from the Wellcome Sanger Institute, Imperial College London, Harvard University in the US and their collaborators used CRISPR prime editing to create multiple versions of human genomes in cell lines, each with different structural changes. Using genome sequencing, they were able to analyze the genetic effects of these structural variations on .

The research, published in Science, shows that as long as essential genes remain intact, our genomes can tolerate significant structural changes, including large deletions of the genetic code. The work opens the door to studying and predicting the role of structural variation in disease.

Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical trials

Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support clinical trials for its epigenome editor.

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic Hepatitis B — a viral infection that damages the liver and affects millions globally. The investment will also support the development of various other therapies, including additional gene, cell and regenerative therapy programs.

“The goal is to epigenetically repress the virus to prevent it from being able to replicate and make the viral proteins that it would normally produce,” said Charles Gersbach, John W. Strohbehn distinguished professor of biomedical engineering and cofounder of Tune Therapeutics.

/* */